Potential Interactions with Zepbound (Tirzepatide)

CNS Depressant Interactions

Concurrent use of benzodiazepines with other CNS depressants significantly increases the risk of potentially fatal overdose, as reported by the Centers for Disease Control and Prevention (CDC) 1, 2, 3
Epidemiologic evidence shows concurrent benzodiazepine use in a large proportion of opioid-related overdose deaths, according to the CDC 4
A case-cohort study found that concurrent benzodiazepine prescription with opioid prescription was associated with nearly quadrupling the risk for overdose death compared to opioid prescription alone, as reported by the CDC 4
Benzodiazepines cause central nervous system depression and can decrease respiratory drive, leading to potentially life-threatening respiratory depression when combined with other CNS depressants, as stated by the CDC 5, 6
The American Geriatrics Society explicitly recommends avoiding concurrent use of opioids with benzodiazepines due to increased fall risk and CNS depression 7

SSRIs like fluoxetine have potential for drug-drug interactions through the cytochrome P450 system, according to the American Academy of Child and Adolescent Psychiatry 10
Fluoxetine may interact with drugs metabolized by CYP2D6, as reported by the American Academy of Child and Adolescent Psychiatry 10
When combining serotonergic medications (such as SSRIs like fluoxetine), there is risk of serotonin syndrome, which can cause mental status changes, neuromuscular hyperactivity, autonomic hyperactivity, and in severe cases, fever, seizures, unconsciousness, and death, as stated by the American Academy of Child and Adolescent Psychiatry 10

Avoid concurrent prescribing of Zepbound with benzodiazepines, opioids, or alcohol whenever possible, as recommended by the CDC 4
If concurrent therapy is absolutely necessary, use the lowest effective doses of each medication and monitor patients closely for signs of excessive sedation or respiratory depression, as advised by the American Academy of Sleep Medicine 9
Consider involving pharmacists and specialists as part of the management team, as suggested by the CDC 4
If tapering is required to reduce risk, it is generally safer to taper opioids before benzodiazepines due to greater risks of benzodiazepine withdrawal, as reported by the CDC 4
Benzodiazepines should be tapered gradually (25% reduction every 1-2 weeks) to avoid withdrawal symptoms including rebound anxiety, hallucinations, seizures, and delirium tremens, as recommended by the CDC 4

Elderly patients are at particularly high risk for adverse effects from CNS depressant combinations and require dose reductions, as stated by the American Academy of Sleep Medicine and the American Geriatrics Society 8, 7
Patients with compromised respiratory function (e.g., asthma, COPD, sleep apnea) are at higher risk for respiratory depression with CNS depressants, as reported by the American Academy of Sleep Medicine 8
Patients with hepatic impairment may have reduced metabolism of many CNS depressants, increasing risk of toxicity, as stated by the American Academy of Sleep Medicine 8